WLLW Stock Overview
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada.
Willow Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.13|
|52 Week High||CA$0.85|
|52 Week Low||CA$0.11|
|1 Month Change||-26.47%|
|3 Month Change||-32.43%|
|1 Year Change||-83.11%|
|3 Year Change||-82.14%|
|5 Year Change||n/a|
|Change since IPO||-95.83%|
Recent News & Updates
Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|WLLW||CA Biotechs||CA Market|
Return vs Industry: WLLW underperformed the Canadian Biotechs industry which returned 7.9% over the past year.
Return vs Market: WLLW underperformed the Canadian Market which returned -2% over the past year.
|WLLW Average Weekly Movement||13.0%|
|Biotechs Industry Average Movement||12.9%|
|Market Average Movement||10.8%|
|10% most volatile stocks in CA Market||19.4%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: WLLW is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: WLLW's weekly volatility (13%) has been stable over the past year.
About the Company
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.
Willow Biosciences Fundamentals Summary
|WLLW fundamental statistics|
Is WLLW overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|WLLW income statement (TTM)|
|Cost of Revenue||CA$22.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.018|
|Net Profit Margin||1,729.92%|
How did WLLW perform over the long term?See historical performance and comparison
Is WLLW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WLLW?
Other financial metrics that can be useful for relative valuation.
|What is WLLW's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does WLLW's PE Ratio compare to its peers?
|WLLW PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
IBT IBEX Technologies
APC Advanced Proteome Therapeutics
MBX Microbix Biosystems
WLLW Willow Biosciences
Price-To-Earnings vs Peers: WLLW is good value based on its Price-To-Earnings Ratio (7x) compared to the peer average (10.2x).
Price to Earnings Ratio vs Industry
How does WLLW's PE Ratio compare vs other companies in the North American Biotechs Industry?
Price-To-Earnings vs Industry: WLLW is good value based on its Price-To-Earnings Ratio (7x) compared to the North American Biotechs industry average (15.7x)
Price to Earnings Ratio vs Fair Ratio
What is WLLW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||7x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate WLLW's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of WLLW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate WLLW's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate WLLW's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Willow Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Willow Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Willow Biosciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Willow Biosciences competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Willow Biosciences performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WLLW has high quality earnings.
Growing Profit Margin: WLLW became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: WLLW has become profitable over the past 5 years, growing earnings by -8.5% per year.
Accelerating Growth: WLLW has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: WLLW has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (47.6%).
Return on Equity
High ROE: WLLW's Return on Equity (8.1%) is considered low.
Discover strong past performing companies
How is Willow Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: WLLW's short term assets (CA$27.2M) exceed its short term liabilities (CA$1.2M).
Long Term Liabilities: WLLW's short term assets (CA$27.2M) exceed its long term liabilities (CA$1.9M).
Debt to Equity History and Analysis
Debt Level: WLLW is debt free.
Reducing Debt: WLLW had no debt 5 years ago.
Debt Coverage: WLLW has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: WLLW has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Willow Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WLLW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WLLW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WLLW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WLLW's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as WLLW has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Seufer-Wasserthal (60 yo)
Dr. Peter Seufer-Wasserthal, Ph D., serves as a Interim President and Chief Executive Officer at Willow Biosciences Inc. since July 17, 2022, Dr. Seufer-Wasserthal serves as Chairman at Willow Biosciences...
Experienced Management: WLLW's management team is considered experienced (2.3 years average tenure).
Experienced Board: WLLW's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Willow Biosciences Inc.'s employee growth, exchange listings and data sources
- Name: Willow Biosciences Inc.
- Ticker: WLLW
- Exchange: TSX
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$15.464m
- Shares outstanding: 123.71m
- Website: https://www.willowbio.com
Number of Employees
- Willow Biosciences Inc.
- 202, 1201-5th Street SW
- T2R 0Y6
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.